The Society of Nuclear Medicine and Molecular Imaging recently wrapped up their 2020 Virtual Annual Meeting, which was held on July 11-14. In response to the pandemic, SNMMI announced in late April that previously scheduled live conference in New Orleans was being replaced with a new virtual format. While vastly
In the United States, heart disease remains the number one cause of death across most groups and accounts for one in every four deaths. Coronary Artery Disease (CAD) is the most common form of heart disease, affecting about 6.7% of adults aged over 20. Within CAD lies an extreme form,
Download the PDF version of this infographic
One unexpected result of the COVID-19 crisis is that I am seeing the best radiation safety and ALARA practices that I’ve experienced in years. Why is that? In short, our newfound interest in social distancing has highlighted the importance of tried-and-true “time, distance, and shielding” principles. Before the pandemic, it
Digirad is celebrating the 20th anniversary of the first commercially performed solid-state nuclear medicine image being scanned. The image was captured in June of 2000 using a Digirad 2020tc and ushered in a new era of imaging to cardiology and nuclear medicine. The development of the solid-state camera began years
Digirad today announced the launch of updated versions of its Ergo general-purpose nuclear camera, and Cardius line of SPECT cameras. The upgraded cameras were developed throughout 2019 and are making their clinical debut this quarter in markets throughout the United States and Canada. The updates bring consolidated functionality, enhanced battery life, and improved portability
The entire medical system of the United States has been focused on a single threat over the past eight weeks. While the dangers from COVID-19 remain present, many states are beginning to open back up, and as capacity increases, medical facilities are easing back into seeing patients. Along with the
While PET MPI has seen increased interest among cardiologists, financial constraints and availability concerns have kept the modality from gaining traction in the US market. The current set of radiopharmaceuticals has built-in drawbacks, but recent innovations could change that. 18F Flurpiridaz is a new agent is showing considerable promise –
